There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ARS Pharmaceuticals (SPRY – Research Report) and Healthequity (HQY – Research Report) with bullish sentiments.
ARS Pharmaceuticals (SPRY)
In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on ARS Pharmaceuticals, with a price target of $13.00. The company’s shares closed last Friday at $3.73, close to its 52-week low of $2.55.
According to TipRanks.com, Argyrides has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
ARS Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
Healthequity (HQY)
In a report released today, Stan Berenshteyn from Wells Fargo maintained a Buy rating on Healthequity, with a price target of $89.00. The company’s shares closed last Friday at $68.99.
According to TipRanks.com, Berenshteyn is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Healthequity with a $83.57 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SPRY:
- ARS Pharmaceuticals reports Q3 EPS (16c), consensus (18c)
- ARS Pharmaceuticals presents clinical data on neffy for allergic reactions
- ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
- ARS Pharmaceuticals announces scheduling of Type A meeting with FDA for neffy
- ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
